ISO 10993 and GOST ISO 10993: Complete Guide to Medical Device Biocompatibility Testing and Requirements
ISO 10993 and GOST ISO 10993 establish internationally recognized biocompatibility testing requirements that medical device manufacturers must meet to demonstrate their products won't cause harmful biological reactions when contacting human tissue.
Start Your Registration Process Today
Contact Us:
8 812-309-89-10
Online Application 
We secure confidential, expedited registrations for domestic and international manufacturers. Expertise includes:
- 30% Faster Approvals via optimized workflows
- Compliance Risk Elimination with pre-submission audits
- Multilingual Support (English/Russian/Chinese) for seamless global collaboration
What is Medical Device Biocompatibility and Why Does It Matter?
Medical device biocompatibility is the ability of a device to not cause unacceptable biological reactions (toxicity, allergy, inflammation, etc.) when in contact with the human body. The ISO 10993 series standards establish unified international requirements for evaluating the biological safety of medical devices.
In this article, we will examine two key documents: the international standard ISO 10993-1:2018 and the Russian version of the standard GOST ISO 10993-1-2021. We'll break down their main requirements, compliance confirmation procedures, and practical application.
Understanding ISO 10993-1:2018 International Biocompatibility Standard
Key Characteristics and Requirements of ISO 10993-1:2018
Full Standard Name: Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk-management process
Key Document Parameters:
| Parameter | Data |
|---|---|
| Publisher | International Organization for Standardization (ISO), technical committee ISO/TC 194 |
| Publication Date | August 2018 (corrected edition - October 2018) |
| Current Status | Active (new 2025 version in preparation) |
| Regional Versions | EN ISO 10993-1:2020 (EU), ANSI/AAMI/ISO 10993-1:2018 (USA) |
| Regulatory Recognition | FDA ("Recognized Consensus Standards" list), EU (harmonized standard MDR 2017/745) |
What is the Purpose and Scope of ISO 10993-1:2018?
The standard is intended for:
- Embedding biocompatibility assessment into the overall risk management process (ISO 14971). This means that safety testing of materials and substances contacting the human body is conducted as part of the overall medical device risk assessment, not separately, to immediately identify possible harmful effects.
- Reducing unnecessary animal testing through a risk-oriented approach. Through preliminary risk assessment and use of alternative methods (such as in vitro tests), excessive animal experiments can be avoided and conducted only when clearly necessary.
- Creating a unified methodology for evaluating the biological safety of medical devices. The standard establishes clear steps and criteria for all types of testing (chemical, toxicological, immunological, etc.) so that results are comparable and recognized worldwide.
ISO 10993-1:2018 simplifies and standardizes the biological safety assurance process for medical devices, making it more integrated, ethical, and transparent.
The standard applies to:
- All types of medical devices (active, non-active, implantable). The standard covers any devices - from simple bandages to complex electronic equipment and implants - to assess their impact on the body.
- Materials with direct or indirect contact with the body. Biocompatibility applies not only to parts that directly contact tissues, but also those that work nearby or within body fluids (such as tubes, catheters).
- Personal protective equipment for medical personnel. ISO 10993-1:2018 also applies to gloves, masks, and other protective equipment that contact the skin or mucous membranes of healthcare workers to prevent allergic and toxic reactions.
ISO 10993-1:2018 ensures that any products and materials contacting people - whether patients or medical personnel - undergo unified biological safety verification.
Essential Terminology and Concepts in ISO 10993-1:2018
| Term | Definition |
|---|---|
| Nature & Duration of Contact | Device classification by contact location and duration (≤ 24 h, > 24 h ≤ 30 days, > 30 days) |
| Endpoint | Specific biological effect for evaluation: cytotoxicity, sensitization, systemic toxicity |
| BEP (Biological Evaluation Plan) | Written plan justifying test selection or omission |
| BER (Biological Evaluation Report) | Final biological safety report |
Step-by-Step Process for ISO 10993-1:2018 Compliance
Biocompatibility Assessment Stages:
- Device categorization according to Table A.1 (contact type × contact time). Determine how the device interacts with the body (skin, blood, internal tissue) and for what duration (short, long-term, etc.) to select the appropriate test battery.
- Collection of existing data from literature, clinical studies, material analysis. Study already available information about materials and similar devices to avoid repeat studies and understand potential risks in advance.
- Risk analysis to identify data gaps (GAP analysis). Compare existing data with testing requirements, identifying what information is missing for complete safety assessment.
- BEP preparation with test selection justification. Prepare a "biocompatibility testing plan" (Biological Evaluation Plan) explaining which tests will be conducted and why.
- Conducting necessary tests in accredited laboratories. Verify toxicity, irritation, allergenicity, and other parameters.
- Results integration into ISO 14971 documentation. Include all conclusions and test data in the risk management report to connect biocompatibility with overall device safety.
- Re-evaluation upon design changes or emergence of new data. Conduct additional checks and update the testing plan whenever materials, design, or new publications change.
These stages ensure a systematic and evidence-based approach: from contact classification to final results integration into risk assessment, guaranteeing device safety throughout their entire lifecycle.
How to Obtain ISO 10993-1:2018 Compliance Confirmation
Required Documentation:
| Evidence Block | Content |
|---|---|
| Materials Science | Chemical characterization (ISO 10993-18), raw material descriptions, coatings |
| Laboratory Protocols | Cytotoxicity (ISO 10993-5), sensitization (-10), irritation (-23) |
| Toxicological Risk Assessment | Expert toxicological evaluation with safe dose calculations |
| BEP + BER | Plan and report in regulator's language |
| QMS Connection | Integration into ISO 13485 quality management system |
Regulatory Compliance and Monitoring for ISO 10993-1:2018
Regulatory Bodies by International Jurisdictions:
| Jurisdiction | Control Body | Verification Methods |
|---|---|---|
| USA | FDA, OHT division | Dossier review in 510(k)/PMA |
| EU | Notified Body (NB) | QMS audit + technical documentation |
| Other Regions | PMDA (Japan), TGA (Australia) | Own guidelines based on ISO 10993 |
Mandatory Status and Benefits of ISO 10993-1:2018
Mandatory Status of ISO 10993-1:2018
- Formally: voluntary international standard
- Practically: de facto mandatory standard for medical device registration
- Alternatives: possible but require lengthy scientific justification
Key Advantages for Manufacturers:
- Accelerated market entry. Document recognized by regulators worldwide
- Testing cost savings. Risk-oriented approach eliminates unnecessary tests
- Reduced post-market risks. Systematic documentation reduces likelihood of medical device recalls
- Integration with other standards. Unified terminology with ISO 14971 and ISO 13485
- Brand protection. Documented medical device safety
Complete Guide to GOST ISO 10993-1-2021 Russian Standard
Official Characteristics of GOST ISO 10993-1-2021
Full Name: "Medical devices. Biological evaluation. Part 1. Evaluation and testing within a risk management process"
Key Document Facts:
| Parameter | Data |
|---|---|
| Development Basis | Literally standardized ("IDT") with ISO 10993-1:2018 |
| Approved By | Interstate Council for Standardization (protocol No. 144-P dated 22.10.2021) |
| Introduction in RF | Rosstandart Order No. 1465-st dated 09.11.2021 |
| Effective Date | March 1, 2022 |
| EAEU Action | Armenia, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan |
| Previous Version Status | Replaces GOST ISO 10993-1-2011 |
Purpose and Key Provisions of GOST ISO 10993-1-2021
The standard establishes requirements for protecting the human body from biological risks associated with medical device use. It is intended for specialists planning research and medical device manufacturers.
Key Provisions of GOST ISO 10993-1-2021:
- Classification of medical devices by nature and duration of contact. The standard divides devices by how and how long they contact human tissues or fluids: surface, short-term (up to 24 h), prolonged (24 h-30 d), and permanent (>30 d) contact.
- Requirements for analyzing information from various sources. It's necessary to collect and systematize data from scientific literature, regulatory documents, supplier materials, and clinical practice to justify biocompatibility.
- GAP analysis of existing data set. Evaluates completeness and relevance of available data, identifies information gaps necessary for safety assessment.
- Determining additional data for biological safety analysis. Based on identified gaps, forms a list of additional in vitro, in vivo, and chemical-physical tests required for complete biological justification.
- General requirements for medical device research. Sets principles for planning, conducting, and documenting tests, including method validation and risk management.
GOST ISO 10993-1-2021 establishes a step-by-step approach to biological evaluation, starting with device classification, through data collection and analysis to developing and conducting necessary tests for safety confirmation.
Scope and Limitations of GOST ISO 10993-1-2021
The standard applies to:
- All types of medical devices (active, non-active, implantable). Covers devices of any functional category regardless of power source or installation location in the body.
- Materials with direct or indirect contact with patient's body. Applies to all device components that contact tissues, blood, or other biological media even through intermediate layers.
- Medical personnel protective equipment (gloves, masks). Includes products not introduced into the patient's body but contacting biological fluids and requiring biocompatibility assessment.
The standard does NOT apply to:
- Hazards related to bacteria, mold, yeast, viruses. The standard doesn't regulate microbiological risks and device sterilization, focusing exclusively on chemical-biological material reactions.
- Transmissible spongiform encephalopathy (TSE) agents. Excludes prion disease transmission risks; TSE issues are regulated by separate documents.
- Other pathogens. The standard doesn't consider specific biosafety requirements regarding any microorganisms - bacteria, fungi, or viruses.
GOST ISO 10993-1:2021 focuses on chemical-toxicological and biological evaluation of medical device materials but doesn't address microbiological or prion risks, which are regulated by other standards.
Key Changes and Updates in GOST ISO 10993-1-2021
Main Innovations of GOST ISO 10993-1-2021 Compared to Previous Versions:
- Appendix A revised. Added columns "physical and/or chemical information" for systematizing material composition and property data, "pyrogenicity" for fever-causing ability assessment, and "chronic toxicity" for long-term exposure.
- Appendix B updated. Introduced new risk management process guidance combining ISO 14971 principles with biological evaluation requirements for a more transparent and structured approach.
- Expanded terms and definitions of ISO 10993 series. Enhanced glossary including new concepts (e.g., "biofilm," "non-contacting device") unifying terminology across all standard parts.
- Added information on non-contacting device evaluation and short-term contact. Clarified requirements for devices contacting patients less than 24 hours or not directly contacting at all, including test selection criteria.
- Included requirements for nanomaterials and absorbable materials. Established specific methodologies for evaluating nanoparticles and materials that degrade or absorb in the body, emphasizing possible unique risks.
- Added reference to ISO 18562 for breathing gases. Recommended applying separate standard (ISO 18562) for evaluating toxicity, condensation, and particles in gas delivery systems used in ventilation and anesthesia.
GOST ISO 10993-1-2021 strengthens systematic and comprehensive biological evaluation through expanding technical requirements, implementing risk-oriented approach, and considering modern materials and device applications.
How to Confirm GOST ISO 10993-1-2021 Compliance in Russia
Compliance Confirmation Steps:
| Stage | What Manufacturer Prepares |
|---|---|
| 1. Laboratory Protocols | From accredited laboratory per GOST ISO 10993-5, -10, -23, etc. |
| 2. BEP / BER | Plan and report in Russian |
| 3. Risk Management File | Per GOST ISO 14971-2023 |
| 4. Registration Dossier | Includes BEP/BER, production schemes, clinical data, QMS certificate |
| 5. Submission to Roszdravnadzor | To obtain registration certificate (RC) |
Regulatory Monitoring and Penalties for Violations
Regulatory Bodies:
| Control Body | Powers |
|---|---|
| Roszdravnadzor | Registration, inspections, post-market surveillance. Can suspend/revoke RC |
| Rosakkreditatsiya | Oversight of testing laboratories |
| Rosstandart | Methodological oversight of GOST application |
Violation Liability:
- Administrative fines under Administrative Code Article 6.33 and 14.43 (up to 1 million rubles for legal entities)
- Registration revocation and product recall from market
- Criminal liability under Criminal Code Article 238 for health damage
Mandatory Status and International Recognition
Mandatory Status in Russia
- Formally: voluntary GOST (like all GOSTs)
- Practically: de facto mandatory for medical device registration
- Justification: Roszdravnadzor checks biocompatibility; easiest to prove through GOST compliance
Connection with International Regulators
| Region/Body | Document | Practical Significance |
|---|---|---|
| EU (MDR 2017/745) | EN ISO 10993-1:2020/AC:2021 | GOST ISO reports accepted as text is identical |
| USA (FDA) | FDA Guidance "Use of ISO 10993-1" (2023) | Recognizes standard without changes |
| Canada, Australia, Japan | National guidelines | Biocompatibility evaluated by same method |
ISO 10993-1:2018 vs GOST ISO 10993-1-2021: Complete Comparison
Technical Similarities Between Standards
Technical Content - "Twins":
| Comparison Criteria | ISO 10993-1:2018 | GOST ISO 10993-1-2021 |
|---|---|---|
| Technical Content | Defines biocompatibility assessment in risk management process | Completely identical ("IDT") to ISO text |
| Structure | 10 sections + 3 appendices (A, B, C) | Exactly same structure |
| Key Terms | Nature & duration of contact, Endpoint, BEP, BER | Same terms in translation + English in brackets |
| Methodology | "First data analysis, then only needed tests" | Completely same approach |
Key Differences Between Standards
| Area | ISO 10993-1:2018 | GOST ISO 10993-1-2021 |
|---|---|---|
| Legal Status | Voluntary consensus standard | Formally voluntary but mentioned in RZN methodologies |
| Publisher | ISO (TC 194) | Eurasian Interstate Council for Standardization |
| Language and Format | English, number ISO 10993-1:2018 | Russian, number GOST ISO 10993-1-2021 |
| Document References | "ISO 14971:2019, ISO 10993-5..." | "GOST ISO 14971-2023, GOST ISO 10993-5-2023..." |
| Compliance Control | FDA, Notified Bodies, PMDA | Roszdravnadzor, Rosakkreditatsiya, EAEU bodies |
Practical Recommendations for Standard Selection
Working Only in EAEU Territory:
- Use GOST ISO 10993-1-2021 in references and reports
- Russian language documentation speeds up Roszdravnadzor expertise
- Laboratories accredited to GOST numbers
Working in International Market:
- Maintain English documentation per ISO
- For each region, adapt only standard numbers and language
- Monitor updates - ISO 10993-1:2025 will come before Russian version
Medical device biosafety strategy should be flexible: use GOST versions within EAEU, duplicate or translate documents for export, and fully transition to international standards and language for global market.
Future Updates and Changes in ISO 10993 Standards
Upcoming ISO 10993-1:2025 Updates and New Features
ISO 10993-1:2025 - New Edition:
- ISO/FDIS 10993-1:2025 draft passed voting in October 2024
- Expected publication during 2025
- Will replace current 2018 edition
Key Innovations in ISO 10993-1:2025:
- Consideration of "sensitive patient populations." Introduces special criteria for evaluating materials and devices for high-risk groups (pediatrics, pregnant women, immunocompromised) to account for their physiological characteristics and possible increased reactivity.
- Expanded evaluation of "reasonably foreseeable misuse." Now necessary to analyze not only normal use but also scenarios of improper installation, cleaning, or dosing that may lead to additional biological risks.
- Separate rules for biodegradable devices. Establishes requirements for evaluating material degradation products, biodegradation rate, and their body impact during degradation process, including long-term accumulation effects.
- Special requirements for "point-of-care" devices. For quickly accessible devices (bedside analyzers, portable test systems), simplified but strict biocompatibility testing protocols are provided considering mobility and diverse application conditions.
ISO 10993-1:2025 expands focus from traditional materials to real-use conditions and vulnerable patient groups, strengthening risk-oriented approach to biological evaluation, especially for new technologies and application scenarios.
Expected GOST Version Updates
GOST Version Planned Updates:
- Russian translation will appear 6-18 months after new ISO standard release
- Will receive new number (presumably GOST ISO 10993-1-2026)
- Will require documentation reference updates
Professional Expert Assistance
ISO 10993-1:2018 and GOST ISO 10993-1-2021 are essentially one standard in two different legal shells. They differ in language, number, and controlling bodies but not in biocompatibility requirements. Main compliance benefits: fast international market entry, testing cost optimization, reduced regulatory risks, legal claim protection, quality management system integration.
Compliance with biocompatibility requirements per ISO 10993 standards is not just regulatory necessity but also competitive advantage ensuring patient and medical community trust in your devices.
LLC UCEC "QUALITY" is an expert team with years of experience in medical device registration and certification. Our specialists deeply know all nuances of current Russian and international legislation, track actual regulatory changes, and are ready to provide professional assistance in solving any issues related to bringing medical devices to RF and EAEU markets.
Frequently Asked Questions (FAQ)
What is ISO 10993 and why is it required for medical devices?
ISO 10993 is an international standard series that establishes requirements for evaluating the biological safety of medical devices. It's essentially required because it ensures that medical devices won't cause harmful biological reactions (like toxicity, allergies, or inflammation) when they contact the human body. While technically "voluntary," it's practically mandatory for medical device registration worldwide since regulatory bodies like the FDA and EU notified bodies recognize it as the gold standard for biocompatibility testing.
What's the difference between ISO 10993-1:2018 and GOST ISO 10993-1-2021?
The standards are technically identical in content - GOST ISO 10993-1-2021 is simply the Russian version that's been translated and adapted for use in Russia and EAEU countries. The key differences are: language (English vs Russian), numbering system, and controlling regulatory bodies. If you're only working in Russia/EAEU territory, use the GOST version. For international markets, stick with the ISO version. The actual biocompatibility requirements and testing procedures are exactly the same.
How do I determine what biocompatibility tests my medical device needs?
Start by classifying your device using Table A.1 in the standard, which categorizes devices by contact type (surface, blood, tissue) and duration (≤24 hours, 24 hours-30 days, >30 days). Then conduct a GAP analysis - collect existing data about your materials from literature, suppliers, and previous studies. Compare this against the testing requirements for your device category to identify what additional tests you need. Create a Biological Evaluation Plan (BEP) documenting your rationale for test selection or omission.
What documents do I need to prove ISO 10993 compliance?
You'll need several key documents: laboratory test reports from accredited labs (cytotoxicity, sensitization, irritation tests as applicable), chemical characterization of materials (ISO 10993-18), a Biological Evaluation Plan (BEP) explaining your test strategy, a Biological Evaluation Report (BER) summarizing all findings, and integration of results into your ISO 14971 risk management file. All documentation should be in the appropriate language for your target regulatory jurisdiction.
How much does ISO 10993 biocompatibility testing typically cost and how long does it take?
Costs vary significantly based on your device category and required tests, typically ranging from $15,000-$100,000+ for a complete biocompatibility package. Basic cytotoxicity tests might cost $2,000-$5,000, while comprehensive testing including systemic toxicity and implantation studies can exceed $50,000. Timeline is usually 8-16 weeks for standard test batteries, though this can extend to 6+ months if animal studies or specialized testing is required. The risk-based approach in ISO 10993-1 can help reduce both costs and timelines by eliminating unnecessary tests through proper data analysis and justification.
Insights & Market Analytics
Dive into expert articles, regulatory trends, and market intelligence shaping the future of compliance and certification in Russia and Eurasia EAEU.
Explore Insights & Articles
Explore Insights & Articles
Company News
Discover the Latest Company News
Discover the Latest Company News
Get Expert Advice from Our Specialists
Our experts are ready to help. Contact us now for professional guidance, and we’ll tailor the perfect solution for your needs.